Press releases are posted on Independent.com as a free community service.
Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback